Standout Papers

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease... 1997 2026 2006 2016 3.7k
  1. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease (2001)
    Yasunori Ogura, Denise K. Bonen et al. Nature
  2. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis (2005)
    Paul Rutgeerts, William J. Sandborn et al. New England Journal of Medicine
  3. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease (1997)
    Stephan R. Targan, Stephen B. Hanauer et al. New England Journal of Medicine
  4. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease (2013)
    William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine
  5. Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease (1999)
    Daniel H. Present, Paul Rutgeerts et al. New England Journal of Medicine
  6. Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial (2006)
    Jean–Frédéric Colombel, William J. Sandborn et al. Gastroenterology
  7. Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy (1994)
    Simon Lichtiger, D. H. Present et al. New England Journal of Medicine
  8. A Simple Classification of Crohnʼs Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 (2000)
    Christoph Gasché, Jürgen Schölmerich et al. Inflammatory Bowel Diseases
  9. A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis (2006)
    Geert D’Haens, William J. Sandborn et al. Gastroenterology
  10. Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease (1999)
    Paul Rutgeerts, Geert D’Haens et al. Gastroenterology
  11. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease (2012)
    William J. Sandborn, Christopher Gasink et al. New England Journal of Medicine
  12. Maintenance Therapy with Certolizumab Pegol for Crohn's Disease (2007)
    Stefan Schreiber, Ian C. Lawrance et al. New England Journal of Medicine
  13. Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis (2011)
    Jean‐Frédéric Colombel, Paul Rutgeerts et al. Gastroenterology
  14. Methotrexate for the Treatment of Crohn's Disease (1995)
    Brian G. Feagan, James Rochon et al. New England Journal of Medicine
  15. A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease (2000)
    Brian G. Feagan, Richard N. Fedorak et al. New England Journal of Medicine
  16. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease (2002)
    William J. Sandborn, Brian G. Feagan et al. Gastroenterology

Immediate Impact

2 by Nobel laureates 47 from Science/Nature 223 standout
Sub-graph 1 of 11

Citing Papers

Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
2021 Standout
Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs
2021 Standout
148 intermediate papers

Works of Stephen B. Hanauer being referenced

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 Standout
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
2012 Standout
and 59 more

Author Peers

Author Last Decade Papers Cites
Stephen B. Hanauer 25150 18694 8824 154 33.0k
Gert Van Assche 26295 20158 10425 445 35.8k
Stephen B. Hanauer 18615 14207 6145 398 24.1k
Stephan R. Targan 17995 12274 5869 428 30.4k
Bruce E. Sands 27560 20316 10502 579 38.2k
Remo Panaccione 25603 18908 9789 684 35.4k
Daniel Rachmilewitz 13437 10262 6122 196 21.1k
Anne M. Griffiths 15754 11072 7093 361 22.4k
Geert D’Haens 30399 23520 11890 897 41.6k
Simon Travis 14524 11373 7291 419 21.1k
Walter Reinisch 13684 10707 5093 334 19.2k

All Works

Loading papers...

Rankless by CCL
2026